与癌症相关的复发ERBB4突变正在转变,并对向疗法产生抗性
Veera K Ojala1,2,3, Sini Ahonen1, Sara Peltola1,2,3,4
1Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.
与癌症相关的ERBB4 (HER4) 突变可以推动癌症生长和对向疗法的耐药性. 某些ERBB4突变对泛ERBB抑制剂敏感,提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 受体氨酸激酶ERBB4 (HER4) 突变与癌症进展和治疗耐药性有关.
- 复发的ERBB4突变通常发生在关键激活区域或模仿已知的瘤突变.
研究的目的:
- 研究与癌症相关的ERBB4突变的功能影响.
- 评估这些突变的致癌潜力和治疗敏感性.
主要方法:
- 基于细胞的转化试验被用来评估瘤潜在.
- 功能性分析的特征是突变驱动的激活,受体合作和药物敏感性.
- 在体外和体外模型中评估了对向疗法的耐药性.
主要成果:
- 在分析的ERBB4突变中,超过一半 (11/18) 在细胞模型中表现出转化活性.
- 强大的突变S303F,E452K和L798R表现出激活特性,与其他ERBB受体合作,对涅拉替尼,阿法替尼和达科米替尼敏感.
- 在EGFR突变肺癌模型中,S303F突变与E715K一起对奥西默蒂尼布产生了耐药性.
结论:
- 复发的ERBB4突变具有显著的致癌潜力,并影响治疗反应.
- 临床上可用的泛ERBB抑制剂对特定的ERBB4突变显示出有效性.
- 这些发现支持对ERBB4突变癌症的泛ERBB抑制剂进行测试,包括在获得耐药性的情况下.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
